Pedro Mata Selected Research

Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)

1/2022	Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care.
1/2022	Familial Hypercholesterolemia and Lipoprotein(a): Two Partners in Crime?
1/2022	Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia.
12/2021	The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia.
8/2021	Detection of Familial Hypercholesterolemia through centralized analytical data. HF HUELVA DETECTA Program.
7/2021	Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience.
5/2021	Alternative C3 Complement System: Lipids and Atherosclerosis.
1/2021	Adherence to a Mediterranean diet, dyslipidemia and inflammation in familial hypercholesterolemia.
10/2020	Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica.
12/2019	Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pedro Mata Research Topics

Disease

45	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2022 - 04/2002
18	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 03/2002
12	Atherosclerosis 01/2022 - 08/2004
11	Hypercholesterolemia 12/2021 - 11/2002
10	Hypertension (High Blood Pressure) 01/2022 - 04/2002
10	Coronary Artery Disease (Coronary Atherosclerosis) 07/2018 - 11/2002
10	Coronary Disease (Coronary Heart Disease) 01/2018 - 08/2002
7	Inflammation (Inflammations) 05/2021 - 01/2003
6	Inborn Genetic Diseases (Disease, Hereditary) 01/2022 - 01/2015
6	Atherosclerotic Plaque (Atheroma) 01/2021 - 09/2012
5	Homozygous Familial Hypercholesterolemia 01/2022 - 03/2015
5	Type 2 Diabetes Mellitus (MODY) 03/2016 - 10/2014
4	Xanthomatosis (Xanthoma) 01/2015 - 09/2005
3	Aortic Valve Stenosis (Aortic Stenosis) 01/2022 - 07/2016
2	Dyslipidemias (Dyslipidemia) 01/2021 - 12/2019
2	Hyperlipidemias (Hyperlipidemia) 10/2014 - 10/2014
2	Muscular Diseases (Myopathy) 03/2005 - 01/2003
1	Body Weight (Weight, Body) 01/2022
1	Vascular Remodeling 05/2021
1	Heart Valve Diseases (Valvular Heart Disease) 01/2021
1	Coronary Stenosis (Coronary Artery Stenosis) 01/2019
1	Pathologic Constriction (Stenosis) 07/2018
1	Hyperlipoproteinemia Type III (Broad Beta Disease) 01/2018
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2015
1	Thrombosis (Thrombus) 11/2015
1	Myocardial Infarction 01/2014
1	Ischemic Stroke 04/2011
1	Peripheral Arterial Disease 04/2011
1	Cognitive Dysfunction 03/2010
1	Heart Diseases (Heart Disease) 09/2004
1	Headache (Headaches) 01/2003
1	Arteriosclerosis 08/2002

Drug/Important Bio-Agent (IBA)

32	LDL CholesterolIBA 01/2022 - 03/2002
26	LipidsIBA 12/2021 - 04/2002
18	oxidized low density lipoproteinIBA 01/2022 - 04/2002
9	Lipoprotein(a)IBA 01/2022 - 05/2014
9	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 07/2021 - 11/2002
7	LDL Receptors (LDL Receptor)IBA 01/2022 - 08/2003
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2018
5	CholesterolIBA 01/2018 - 08/2002
4	HDL CholesterolIBA 01/2022 - 03/2002
4	LDL Lipoproteins (beta Lipoproteins)IBA 01/2022 - 02/2014
4	CalciumIBA 12/2021 - 07/2018
4	Ezetimibe (Zetia)FDA Link 03/2016 - 11/2002
3	MicroRNAs (MicroRNA)IBA 01/2021 - 01/2018
3	DNA (Deoxyribonucleic Acid)IBA 11/2018 - 07/2005
2	Triglycerides (Triacylglycerol)IBA 01/2022 - 04/2015
2	Lipoproteins (Lipoprotein)IBA 05/2021 - 09/2004
2	Chemokine ReceptorsIBA 02/2018 - 01/2018
2	Cytidine Monophosphate (CMP)IBA 11/2015 - 08/2013
2	Atorvastatin (Lipitor)FDA Link 04/2008 - 09/2004
2	Transaminases (Aminotransferases)IBA 03/2005 - 01/2003
2	Simvastatin (Zocor)FDA LinkGeneric 03/2005 - 02/2005
2	Apolipoprotein B-100 (Apo B 100)IBA 08/2003 - 11/2002
1	Proprotein Convertase 9IBA 12/2021
1	evolocumabIBA 07/2021
1	alirocumabIBA 07/2021
1	PCSK9 InhibitorsIBA 07/2021
1	Complement C3 (C3 Complement)IBA 05/2021
1	BMS201038IBA 01/2019
1	Monoclonal AntibodiesIBA 01/2019
1	low density lipoprotein inhibitorIBA 01/2017
1	N-n-propyl-N-formylhydrazineIBA 01/2017
1	HDL LipoproteinsIBA 01/2016
1	Glucose (Dextrose)FDA LinkGeneric 12/2015
1	Interleukin-4 Receptors (Interleukin 4 Receptor)IBA 07/2014
1	Retinol-Binding Proteins (Retinoid Binding Proteins)IBA 01/2014
1	EpitopesIBA 01/2014
1	Messenger RNA (mRNA)IBA 09/2012
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 06/2012
1	Pharmaceutical PreparationsIBA 06/2012
1	Prealbumin (Transthyretin)IBA 05/2012
1	Factor VII (Proconvertin)IBA 04/2011
1	Apolipoprotein E4IBA 03/2010
1	A-Form DNA (A-DNA)IBA 06/2009
1	Apolipoproteins B (ApoB)IBA 10/2005
1	ApolipoproteinsIBA 11/2002
1	CarbohydratesIBA 08/2002
1	Biological ProductsIBA 08/2002

Therapy/Procedure

9	Therapeutics 05/2021 - 11/2002
2	Mediterranean Diet 01/2021 - 12/2019
1	Liver Transplantation 01/2022
1	Caloric Restriction 01/2022
1	Blood Component Removal (Apheresis) 01/2019
1	Precision Medicine 04/2017